TWST: twistbioscience.com Enterprise Value to EBITDA Ratio
Twist Bioscience (TWST) leads the synthetic biology sector by producing DNA on silicon chips for bioengineering. The EV/EBITDA metric, accounting for debt and amortization, reflects the current market phase, where the value 0.00 determines this level. Despite rapid ARR growth, significant cash burn and patent disputes hinder the company, constraining its path to net profitability.
TWST (twistbioscience.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- market capitalization information:
- business book valuation details:
- debt and solvency information:
Debt to Equity Twist Bioscience|TWST - Long-Term Liabilities to Capital|Short-Term Debt to Equity Twist Bioscience, Inc.|TWST - Company Total Debt Obligations|Debts to Book Capitalization Twist Bioscience Corp|TWST - Company Long-Term Liabilities|Company Short-Term Debts Twist Bioscience|Quick Ratio twistbioscience.com
- financial results and valuation multiples details:
TWST - Company Net Income|Expected Profit Twist Bioscience|TWST - Price to Earnings Multiple|Forward P/E Multiple Twist Bioscience|TWST - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Twist Bioscience Corp|TWST - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Twist Bioscience|TWST - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months twistbioscience.com|TWST - Net earnings per share growth this year|Net earnings per share growth forecast for next year Twist Bioscience
Comprehensive company analysis:Twist Bio TWST
DNA synthesis on silicon platforms requires significant capital expenditures, which is why the EV/EBITDA ratio allows for an assessment of the efficiency of Twist Bioscience (TWST) robotic factories without accounting for tax burdens or debt obligations. By analyzing the historical EV/EBITDA multiple, an investor can determine the real value of Twist Bioscience (TWST) assets, eliminating market noise and the risk of overpaying for temporary growth.
Competitors of Twist Bioscience (TWST)
tempus.com - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio QGEN (Qiagen Corp)|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA: EV/EBITDA Multiple|CRSP (CRISPR Therapeutics Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|SRPT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 10x Genomics TXG|Total Company Value to Operating Income Before Depreciation Ratio Intellia Therapeutics Inc (NTLA)|Stoke - EV/EBITDA Multiple|BioLife (BLFS) - Enterprise Value to EBITDA Ratio|WVE: EV/EBITDA Multiple|MAZE - Total Company Value to Operating Income Before Depreciation Ratio|SION (Sionna Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Prime Medicine Inc PRME|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Taysha (TSHA)|uniQure Pharma - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple MGTX (MeiraGTx Holdings plc)|RGNX - Enterprise Value to EBITDA Ratio|Solid Biosciences - EV/EBITDA Multiple|Company Value to EBITDA Ocugen Inc|PACB (Pacific Biosciences of California) - Enterprise Value to EBITDA Ratio|BNTC: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio DSGN|Enterprise Value to EBITDA Ratio rocketpharma.com (RCKT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics, Inc. (FDMT)|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|Korro Bio - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio EDIT (Editas Corp)|Silence Therapeutics - EV/EBITDA Multiple|PRQR (ProQR Therapeutics N.V.) - Enterprise Value to Operating Income Before Depreciation|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SGMO|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Metagenomi Therapeutics|Enterprise Value to EBITDA Ratio DTIL (Precision BioSciences)|Enterprise Value to Operating Income Before Depreciation Ratio GBIO|Boundless Bio - Enterprise Value to EBITDA Ratio|XCUR - Enterprise Value to EBITDA Ratio|Celsion Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals PHIO|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RNAZ - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BNGO|APDN (Applied DNA Sciences Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BLUE (Bluebird Bio)|IPA (immunoprecise.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMGA (Omega Therapeutics)|singulargenomics.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Syros Pharmaceuticals Inc. SYRS|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA TRACON Pharmaceuticals, Inc (TCON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
